Literature DB >> 11932263

Clinical review 145: Pleiotropic effects of statins: lipid reduction and beyond.

S I McFarlane1, R Muniyappa, R Francisco, J R Sowers.   

Abstract

There is accumulating evidence that statins have beneficial effects that are independent of their classical actions on lipoproteins. These effects include reductions in inflammation in the vasculature, kidney, and bone. Potential beneficial effects of these agents include enhancement of nitric oxide production in vasculature and the kidney. These agents appear to reduce bone fractures and may improve insulin sensitivity and reduce the likelihood of persons progressing from impaired glucose tolerance to type II diabetes. Potential beneficial pleiotropic effects of statins are covered in this review.

Entities:  

Mesh：

Substances：

Year:  2002        PMID： 11932263     DOI： 10.1210/jcem.87.4.8412

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN： 0021-972X            Impact factor:   5.958


  79 in total

1.  Heart protection study: a focus on diabetic patients.

Authors:  Cristina Ogrin; Alexander Perkelvald; Nathaniel Winer
Journal:  Curr Diab Rep       Date:  2004-06       Impact factor: 4.810

Review 2.  Lipids and diabetic nephropathy.

Authors:  Rey F Rosario; Sharma Prabhakar
Journal:  Curr Diab Rep       Date:  2006-12       Impact factor: 4.810

Review 3.  Inflammation and diabetic nephropathy.

Authors:  Carmen Mora; Juan F Navarro
Journal:  Curr Diab Rep       Date:  2006-12       Impact factor: 4.810

Review 4.  Statins and CVD prevention in the diabetic population: implications of the CARDS trial.

Authors:  Omar Murad; John Palmer; James Sowers; Samy I McFarlane
Journal:  Curr Diab Rep       Date:  2005-06       Impact factor: 4.810

5.  Atorvastatin does not decrease or delay diabetes onset in two different mouse models of type 1 diabetes.

Authors:  X Palomer; L Calpe-Berdiel; J Verdaguer; J Carrillo; X Pastor; D Mauricio; F Blanco-Vaca
Journal:  Diabetologia       Date:  2005-06-30       Impact factor: 10.122

Review 6.  The metabolic syndrome.

Authors:  Marc-Andre Cornier; Dana Dabelea; Teri L Hernandez; Rachel C Lindstrom; Amy J Steig; Nicole R Stob; Rachael E Van Pelt; Hong Wang; Robert H Eckel
Journal:  Endocr Rev       Date:  2008-10-29       Impact factor: 19.871

7.  Importance of the lipid-related pathways in the association between statins, mortality, and cardiovascular disease risk: The Multi-Ethnic Study of Atherosclerosis.

Authors:  Denis Talbot; Joseph A Chris Delaney; Veit Sandfort; David M Herrington; Robyn L McClelland
Journal:  Pharmacoepidemiol Drug Saf       Date:  2018-02-06       Impact factor: 2.890

Review 8.  Immunological aspects of atherosclerosis.

Authors:  S Garrido-Urbani; M Meguenani; F Montecucco; B A Imhof
Journal:  Semin Immunopathol       Date:  2013-11-09       Impact factor: 9.623

9.  Original Research: Atorvastatin prevents rat cardiomyocyte hypertrophy induced by parathyroid hormone 1-34 associated with the Ras-ERK signaling.

Authors:  Xiaogang Liu; Chunbo Zou; Chengyuan Yu; Rujuan Xie; Manshu Sui; Suhong Mu; Li Li; Shilei Zhao
Journal:  Exp Biol Med (Maywood)       Date:  2016-05-10

10.  Atorvastatin and celecoxib in combination inhibits the progression of androgen-dependent LNCaP xenograft prostate tumors to androgen independence.

Authors:  Xi Zheng; Xiao-Xing Cui; Zhi Gao; Yang Zhao; Yong Lin; Weichung Joe Shih; Mou-Tuan Huang; Yue Liu; Arnold Rabson; Bandaru Reddy; Chung S Yang; Allan H Conney
Journal:  Cancer Prev Res (Phila)       Date:  2010-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.